Drugs / Mylanta
last change Nov 2023 re-read 2 minutes ago

Mylanta

Developed for
dyspepsia

Trials 0

Also used as a comparator or background therapy in 1 trial
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 4 NCT06241183 Comparator Nov 2023 → Dec 2027 expected dyspepsia, gastroesophageal reflux disease Stony Brook University Recruiting No outcome recorded

Evidence & citations 2 cited values

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as Mylanta ClinicalTrials.gov intervention name — accepted as the source's own label NCT06241183
Route Oral “30 ml of oral Maalox/ Mylanta” NCT06241183